Brokers Issue Forecasts for IDEAYA Biosciences, Inc.'s Q1 2025 Earnings (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Wedbush issued their Q1 2025 EPS estimates for shares of IDEAYA Biosciences in a report released on Tuesday, May 7th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($0.72) for the quarter. Wedbush has a "Outperform" rating and a $52.00 price objective on the stock. The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($2.26) per share. Wedbush also issued estimates for IDEAYA Biosciences' Q2 2025 earnings at ($0.74) EPS, Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.78) EPS and FY2028 earnings at $4.10 EPS.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 23.00%. During the same quarter in the previous year, the firm posted ($0.49) earnings per share. The business's revenue for the quarter was down 100.0% compared to the same quarter last year.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $51.00 to $57.00 and gave the company an "overweight" rating in a research report on Friday, February 23rd. Leerink Partnrs reaffirmed an "outperform" rating on shares of IDEAYA Biosciences in a research report on Friday, February 23rd. Citigroup increased their price objective on IDEAYA Biosciences from $40.00 to $60.00 and gave the company a "buy" rating in a report on Thursday, March 21st. BTIG Research initiated coverage on shares of IDEAYA Biosciences in a report on Friday, March 8th. They issued a "buy" rating and a $55.00 target price for the company. Finally, Capital One Financial reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Thursday, February 22nd. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $47.50.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock traded down $0.77 during trading on Thursday, hitting $40.64. 406,388 shares of the stock were exchanged, compared to its average volume of 829,828. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -20.22 and a beta of 0.83. The firm's 50-day moving average price is $42.57 and its 200 day moving average price is $38.40. IDEAYA Biosciences has a 12-month low of $20.68 and a 12-month high of $47.74.

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the firm's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now directly owns 24,531 shares in the company, valued at approximately $1,128,916.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other IDEAYA Biosciences news, insider Briseno Andres Ruiz sold 2,000 shares of the firm's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $46.02, for a total transaction of $92,040.00. Following the completion of the transaction, the insider now directly owns 24,531 shares in the company, valued at approximately $1,128,916.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Yujiro S. Hata sold 23,557 shares of the firm's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $45.54, for a total transaction of $1,072,785.78. Following the transaction, the chief executive officer now owns 677,887 shares of the company's stock, valued at $30,870,973.98. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of IDYA. Bank of New York Mellon Corp grew its holdings in shares of IDEAYA Biosciences by 12.7% during the third quarter. Bank of New York Mellon Corp now owns 196,289 shares of the company's stock worth $5,296,000 after buying an additional 22,121 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of IDEAYA Biosciences by 206.1% during the third quarter. TD Asset Management Inc now owns 113,656 shares of the company's stock worth $3,066,000 after buying an additional 76,528 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of IDEAYA Biosciences by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,474 shares of the company's stock worth $40,000 after buying an additional 723 shares in the last quarter. Teacher Retirement System of Texas grew its holdings in shares of IDEAYA Biosciences by 6.7% during the third quarter. Teacher Retirement System of Texas now owns 13,741 shares of the company's stock worth $371,000 after buying an additional 867 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of IDEAYA Biosciences by 4.9% during the third quarter. Principal Financial Group Inc. now owns 14,415 shares of the company's stock worth $389,000 after buying an additional 676 shares in the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.